Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
44.61
-0.22 (-0.49%)
At close: Mar 28, 2025, 4:00 PM
44.01
-0.60 (-1.34%)
After-hours: Mar 28, 2025, 5:31 PM EDT
Merus Revenue
In the year 2024, Merus had annual revenue of $36.13M, down -17.78%. Merus had revenue of $9.14M in the quarter ending December 31, 2024, with 2.25% growth.
Revenue (ttm)
$36.13M
Revenue Growth
-17.78%
P/S Ratio
79.29
Revenue / Employee
$112,564
Employees
321
Market Cap
3.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.13M | -7.81M | -17.78% |
| Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
| Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
| Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
| Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
MRUS News
- 4 weeks ago - Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma - GlobeNewsWire
- 6 weeks ago - Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit - GlobeNewsWire
- 7 weeks ago - New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer - GlobeNewsWire
- 2 months ago - Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff - Seeking Alpha
- 2 months ago - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - GlobeNewsWire
- 3 months ago - Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewsWire